ABCB1 Haplotypes Do Not Influence Transport or Efficacy of Tyrosine Kinase Inhibitors in Vitro

Pharmacogenomics and Personalized Medicine - New Zealand
doi 10.2147/pgpm.s45522
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Transport of Six Tyrosine Kinase Inhibitors: Active or Passive?

ADMET and DMPK
PharmacologyHealthMedicineToxicologyChemistryPharmaceutics
2016English

Tyrosine Kinase Inhibitors in Lung Cancer

Hematology/Oncology Clinics of North America
OncologyHematology
2012English

Personalized Therapy of Tyrosine Kinase Inhibitors

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
2013English

Tyrosine Kinase Inhibitors for Diabetes

Science-Business eXchange
2008English

Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer

Journal of the Siena Academy of Sciences
2012English

Small Molecule FLT3 Tyrosine Kinase Inhibitors

2012English

Small Molecule Tyrosine Kinase Inhibitors in Pancreatic Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Do Tyrosine Kinase Inhibitors Lose Favor in Treatment of First-Line Metastatic Renal Cell Carcinoma?

Future Oncology
MedicineCancer ResearchOncology
2019English

Cardiotoxicity Monitoring in Patients Treated With Tyrosine Kinase Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy